# NCT02122913 (NCT02122913)

> A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02122913
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Solid Tumors Harboring NTRK Fusion
- Interventions: Larotrectinib (Vitrakvi, BAY2757556)
- Enrollment: 75
- Primary outcome: Number of participants with adverse events
- Primary outcome: Severity of adverse events
- Primary outcome: Maximum tolerated dose (MTD)
- Primary outcome: Recommended dose for dose expansion

## Indexed commentary on NCT02122913 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02122913